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WE HAVE SHOWN the beneficial effects of an immu-
nomodulation strategy for small intestinal trans-
plantation (SITx) by depleting mature lymphocytes from 
the graft and simultaneously infusing progenitor-rich donor 
bone marrow (BM) cells.! In this study we evaluated the 
relative benefit of leukocyte elimination between ex vivo 
graft irradiation versus donor pretreatment with antilym-
phocyte serum (ALS) in a model of fully allogenic rat SITx. 
Special attention was paid to their impact on early immune 
responses after SITx by analyzing the levels and lineages of 
chimerism as well as the cytokine up-regulation in recipient 
spleen and allografts. 
METHODS 
Orthotopic SITx was performed in Brown Norway (BN, RTln) to 
Lewis (LEW, RTl') rat strain combination using a short course of 
tacrolirnus treatment (1.0 mglkgld, days 0 to 13, 20, and 27, 1M). 
Three groups of recipients were studied: (1) controls without 
immunomodulation, (2) donor ALS pretreatment for 3 days (1.0 
mUd, IP) plus donor BM infusion (2.5 X 108 cells on day 0), and 
(3) ex vivo allograft irradiation (10 Gy) plus donor BM infusion. All 
recipients were followed for 150 days. Levels and lineages of 
chimerism were studied by flow cytometry. Cytokine mRNA levels 
were analyzed by RNase protection assay (RPA). 
RESULTS 
All recipients in this study survived for > 150 days. The 
numbers of donor cells in recipient spleen and blood within 
7 days after SITx were significantly greater among Group 1 
than immunomodulated Group 2 and 3 recipients (Table 
1). The decrease in donor cells among Group 2 hosts was 
mainly caused by the depletion of a/nCR + cells, while the 
number of donor B cells was maintained (data not shown). 
In contrast, all lineages of donor cells were eliminated in 
Group 3, resulting in a low level of chimerism. Analysis of 
lymphocytes in graft mesenteric lymph nodes (MLN) 
showed prompt replacement of donor cells with recipient 
lymphocytes in immunomodulated Group 2 and 3 com-
pared with Group 1. Immunomodulation with ex vivo graft 
irradiation resulted in a more rapid replacement of cells 
than ALS donor pretreatment. The percentage of donor 
cells in MLN 3 days after SITx was 50.5% in Group 1, 
whereas it was 20.8% and 2.5% for Group 2 and 3, 
respectively. mRNA levels for Thl-type cytokines (IL-2 and 
"1-IFN) were increased in spleen and graft MLN of Group 
1 recipients early after SITx (day 1 to 7); however, these 
cytokines were significantly down-regulated in Group 2 and 
3. Histopathological analysis of allografts at day 150 re-
vealed the development of chronic rejection (lymphoid 
depletion, fibrotic changes of Peyer's patches and MLN, 
and existence of arteritis) in Group 1. These changes were 
completely prevented in immunomodulated Group 2 and 3 
allo grafts. 
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Table 1. Chimerism, Cytokine Activity, and Graft Histopathology After Small Intestinal Transplantation With Immunomodulation 
Using Donor ALS Pretreatment or Ex Vivo Graft Irradiation 
% of Donor Cells (Day 3)8 Cytokine mRNA Level (Day 1) (% GAPDH)b Histopathology of the graft 
Spleen T Spleen 8 Spleen Lymphoid 
Cells Cells MLN Spleen IL-2 IFNy MLN IL-2 MLN IFNy Component Arteritis 
1. Control 4.6 :!: 2.4 5.1 :!: 0.6 SO.S:!: 1.4 3.1 :!: 0.2 1.9 :!: 1.1 3.6:!: 1.1 3.0:!: 0.9 atrophy + 
2. AL8 + BM 1.3:!: 0.4 4.5:!: 0.3 20.8 :!: 1.1* 0.3 :!: 0.1* 0.8 :!: 0.8" 1.1 :!: 0.1" 0.7:!: 0.5 well preserved 
3. Rad + BM 0.1 :': 0.1" 0.8 :!: 0.6* 2.S:!: 1.3" 1.4:':0.9" 0.9:': 0.5" 0.8 :': 0.2" 0.1 :!: 0.3* well preserved 
"determined by two-color flow cytometry using mAbs specific for MHC class I antigens on LEW and 8N, and lineage specific mAbs R7.3 (a/3TCR+ cells) and OX33 
(8 cells). 
bmRNA levels were expressed as a ratio of cytokine/GAPDH. 
'p < .05 vs control (ANOVA). 
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IMMUNOMODULATION OF INTESTINAL TRANSPLANTATION 
CONCLUSIONS 
Immunomodulation of SITx either by donor pretreatment 
with ALS or by ex vivo graft irradiation plus donor BM 
infusion improved intestinal allograft outcome by inhibiting 
the development of chronic rejection. Early down-regula-
987 
tion in allografts and recipient spleen of Thl-type cyto-
kines may playa role in the immunomodulation strategy. 
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